BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

Core Insights - BioAtla, Inc. is a clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors [1][3] - The company announced two abstracts accepted for poster presentations at the European Lung Cancer Congress (ELCC) 2025 and the Mayo Clinic Multidisciplinary Head and Neck Cancer Symposium 2025 [1][2] Company Overview - BioAtla operates in San Diego, California, and Beijing, China, through a partnership with BioDuro-Sundia for preclinical development services [3] - The company utilizes proprietary CAB technology to develop novel monoclonal and bispecific antibodies, aiming for selective targeting, greater efficacy, lower toxicity, and cost-efficient manufacturing compared to traditional antibodies [3] - BioAtla holds extensive patent coverage with over 780 active patent matters, including more than 500 issued patents, covering methods of making, screening, and manufacturing CAB product candidates [3] Clinical Development - BioAtla has two first-in-class CAB programs in Phase 2 clinical testing: mecbotamab vedotin (CAB-AXL-ADC) and ozuriftamab vedotin (CAB-ROR2-ADC) [3] - The company is also developing evalstotug, a Phase 2 CAB-CTLA-4 antibody designed to reduce systemic toxicity and enable safer combination therapies with checkpoint inhibitors [3] - The first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development, targeting EpCAM on adenocarcinomas while engaging human CD3 expressing T cells [3]